High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499 · see citing works

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with <i>EGFR</i> -Mutant Lung Cancers

Yu, H. A., Arcila, M. E., Rekhtman, N., Sima, C. S., Zakowski, M. F., Pao, W., Kris, M. G., Miller, V. A., Ladanyi, M., & Riely, G. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2246 · Cited by 2,454 · see citing works

AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

Cross, D. A. E., Ashton, S. E., Ghiorghiu, S., Eberlein, C., Nebhan, C. A., Spitzler, P. J., Orme, J. P., Finlay, M. R. V., Ward, R. A., Mellor, M. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0337 · Cited by 2,246 · see citing works

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing

Frampton, G. M., Fichtenholtz, A., Otto, G. A., Wang, K., Downing, S. R., He, J., Schnall-Levin, M., White, J., Sanford, E. M., An, P., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2696 · Cited by 2,157 · see citing works

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

Jänne, P. A., Yang, J. C.-H., Kim, D.-W., Planchard, D., Ohe, Y., Ramalingam, S. S., Ahn, M.-J., Kim, S.-W., Su, W.-C., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411817 · Cited by 2,116 · see citing works

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

Thress, K. S., Paweletz, C. P., Felip, E., Cho, B. C., Stetson, D., Dougherty, B., Lai, Z., Markovets, A., Vivancos, A., Kuang, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3854 · Cited by 1,589 · see citing works

The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies

Niederst, M. J., Hu, H., Mulvey, H. E., Lockerman, E. L., Garcia, A. R., Piotrowska, Z., Sequist, L. V., & Engelman, J. A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0560 · Cited by 583 · see citing works

Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification

Ou, S. I., Kwak, E. L., Siwak, C. T., Dy, J., Bergethon, K. E., Clark, J. W., Camidge, D. R., Solomon, B., Maki, R. G., Bang, Y., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31821528d3 · Cited by 435 · see citing works

EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients

Planchard, D., Loriot, Y., André, F., Gobert, A., Auger, N., Lacroix, L., & Soria, J. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv319 · Cited by 312 · see citing works

Acquired Resistance ofEGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor

Yu, H. A., Tian, S. K., Drilon, A. E. D. C., Borsu, L. A., Riely, G. J., Arcila, M. E., & Ladanyi, M. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.1066 · Cited by 245 · see citing works

Mechanisms of Acquired Resistance to AZD9291

Kim, T. M., Song, A., Kim, D., Kim, S., Ahn, Y., Keam, B., Jeon, Y. K., Lee, S., Chung, D. H., & Heo, D. S. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000688 · Cited by 225 · see citing works

EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer

Amato, K. R., Wang, S., Tan, L., Hastings, A. K., Song, W., Lovly, C. M., Meador, C. B., Ye, F., Wang, L., Balko, J. M., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-0717 · Cited by 120 · see citing works

Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer

Song, H., Jung, K. S., Yoo, K. H., Cho, J., Lee, J. Y., Lim, S. H., Kim, H. S., Sun, J., Lee, S., Ahn, J. S., et al. (2015) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.12.093 · Cited by 114 · see citing works

Assessment of Resistance Mechanisms and Clinical Implications in Patients With <i>EGFR</i> T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib

Oxnard, G. R., Hu, Y., Mileham, K. F., Husain, H., Costa, D. B., Tracy, P., Feeney, N., Sholl, L. M., Dahlberg, S. E., Redig, A. J., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.2969 · Cited by 686 · see citing works

Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers

Blakely, C. M., Watkins, T. B. K., Wu, W., Gini, B., Chabon, J. J., McCoach, C. E., McGranahan, N., Wilson, G. A., Birkbak, N. J., Olivas, V. R., et al. (2017) · Nature Genetics · doi:10.1038/ng.3990 · Cited by 571 · see citing works

Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients

Yang, Z., Yang, N., Ou, Q., Xiang, Y., Jiang, T., Wu, X., Bao, H., Tong, X., Wang, X., Shao, Y. W., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2310 · Cited by 542 · see citing works

Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management

Cooper, A. J., Sequist, L. V. D., & Lin, J. J. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00639-9 · Cited by 525 · see citing works

Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in <i>EGFR</i> -Mutant NSCLC

Le, X., Puri, S., Negrao, M. V., Nilsson, M. B., Robichaux, J., Boyle, T., Hicks, J. K., Lovinger, K. L., Roarty, E., Rinsurongkawong, W., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1542 · Cited by 387 · see citing works

Third generation EGFR TKIs: current data and future directions

Tan, C., Kumarakulasinghe, N. B., Huang, Y., Ang, Y. L. E., Choo, J. R.-E., Goh, B.-C., & Soo, R. A. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0778-0 · Cited by 317 · see citing works

Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies

Lim, S. M., Syn, N. L. X., Cho, B. C., & Soo, R. A. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.02.006 · Cited by 289 · see citing works

Emerging role of tumor cell plasticity in modifying therapeutic response

Qin, S., Jiang, J., Lü, Y., Nice, E. C., Huang, C., Zhang, J., & He, W. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00313-5 · Cited by 274 · see citing works

MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer

Wang, Q., Yang, S., Wang, K., & Sun, S. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0759-9 · Cited by 267 · see citing works

Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021

Wu, Q., Qian, W., Sun, X., & Jiang, S. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01362-9 · Cited by 202 · see citing works

Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review

Piper‐Vallillo, A. J., Sequist, L. V. D., & Piotrowska, Z. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03123 · Cited by 189 · see citing works

Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance

Minari, R., Bordi, P., & Tiseo, M. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.12.02 · Cited by 186 · see citing works

Combination Osimertinib and Gefitinib in C797S and T790M EGFR-Mutated Non–Small Cell Lung Cancer

Arulananda, S., Do, H., Musafer, A., Mitchell, P., Dobrovic, A., & John, T. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.08.006 · Cited by 184 · see citing works

Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer

Yochum, Z. A., Cades, J., Wang, H., Chatterjee, S., Simons, B. W., O’Brien, J. P., Khetarpal, S. K., Lemtiri-Chlieh, G., Myers, K. V., Huang, E. H. ‐., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0482-y · Cited by 178 · see citing works

Crizotinib in Patients With MET-Amplified NSCLC

Camidge, D. R., Otterson, G. A., Clark, J. W., Ou, S. I., Weiss, J. M., Ades, S., Shapiro, G. I., Socinski, M. A., Murphy, D. A., Conte, U., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.02.010 · Cited by 172 · see citing works

Recent Progress of Small-Molecule Epidermal Growth Factor Receptor (EGFR) Inhibitors against C797S Resistance in Non-Small-Cell Lung Cancer

Chen, L., Fu, W., Zheng, L., Liu, Z., & Liang, G. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01310 · Cited by 167 · see citing works

Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer

Ricordel, C., Friboulet, L., Facchinetti, F., & Soria, J. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx705 · Cited by 155 · see citing works

Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/G and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib

Ou, S. I., Cui, J., Schrock, A. B., Goldberg, M. E., Zhu, V. W., Albacker, L. A., Stephens, P. J., Miller, V. A., & Ali, S. M. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.04.003 · Cited by 152 · see citing works

Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation

Shi, P., Oh, Y.-T., Deng, L. H., Zhang, G., Qian, G., Zhang, S., Ren, H. J., Wu, G., Legendre, B., Anderson, E., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1574 · Cited by 147 · see citing works

Current Molecular-Targeted Therapies in NSCLC and Their Mechanism of Resistance

Schrank, Z., Chhabra, G., Lin, L. Y.-C., Iderzorig, T., Osude, C., Khan, N. H., Kuckovic, A., Singh, S., Miller, R. J., & Puri, N. (2018) · Cancers · doi:10.3390/cancers10070224 · Cited by 143 · see citing works

Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors

Schrock, A. B., Zhu, V. W., Hsieh, W.-S., Madison, R. W., Creelan, B., Silberberg, J., Costin, D., Bharne, A., Bonta, I. R., Bosemani, T., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.05.027 · Cited by 146 · see citing works

Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer

Coleman, N., Hong, L., Zhang, J., Heymach, J. V., Hong, D. S., & Le, X. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100319 · Cited by 132 · see citing works

Discovery of potent epidermal growth factor receptor (EGFR) degraders by proteolysis targeting chimera (PROTAC)

Zhang, H., Zhao, H., Xi, X.-X., Liu, Y., Xin, M., Mao, S., Zhang, J., Lu, A., & Zhang, S. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112061 · Cited by 129 · see citing works

Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies

Tang, Z.-H., & Lu, J. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.02.004 · Cited by 127 · see citing works

Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical Results and Clinical Outcomes

Yang, Z., & Tam, K. Y. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.22955 · Cited by 105 · see citing works

Acquired resistance mechanisms to osimertinib: The constant battle

Zalaquett, Z., Hachem, M. C. R., Kassis, Y., Hachem, S., Eid, R., Kourié, H. R., & Planchard, D. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102557 · Cited by 97 · see citing works

Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy

Santarpía, M., Liguori, A., Karachaliou, N., González‐Cao, M., Daffinà, M. G., D’Aveni, A., Marabello, G., Altavilla, G., & Rosell, R. (2017) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s119644 · Cited by 100 · see citing works

MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer

Cho, B. C., Felip, E., Hayashi, H., Thomas, M., Lu, S., Besse, B., Sun, T., Martinez, M., Sethi, S. N., Shreeve, S. M., et al. (2022) · Future Oncology · doi:10.2217/fon-2021-0923 · Cited by 95 · see citing works

Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism–Mediated Osimertinib Resistance in EGFR- Mutant Lung Cancer

Tanimoto, A., Takeuchi, S., Arai, S., Fukuda, K., Yamada, T., Roca, X., Ong, S. T., & Yano, S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2271 · Cited by 88 · see citing works

Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR -Mutant Non–Small Cell Lung Cancer Cells

Namba, K., Shien, K., Takahashi, Y., Torigoe, H., Sato, H., Yoshioka, T., Takeda, T., Kurihara, E., Ogoshi, Y., Yamamoto, H., et al. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0628 · Cited by 86 · see citing works

Emerging Approaches to Overcome Acquired Drug Resistance Obstacles to Osimertinib in Non-Small-Cell Lung Cancer

Shaikh, M., Shinde, Y., Pawara, R. H., Noolvi, M. N., Surana, S. J., Ahmad, I., & Patel, H. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00876 · Cited by 81 · see citing works

Tolerable and Effective Combination of Full-Dose Crizotinib and Osimertinib Targeting MET Amplification Sequentially Emerging after T790M Positivity in EGFR- Mutant Non–Small Cell Lung Cancer

York, E. R., Varella-Garcia, M., Bang, T. J., Aisner, D. L., & Camidge, D. R. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.02.020 · Cited by 76 · see citing works

Discovery of novel 9-heterocyclyl substituted 9H-purines as L858R/T790M/C797S mutant EGFR tyrosine kinase inhibitors

Lei, H., Fan, S., Zhang, H., Liu, Y.-J., Hei, Y., Zhang, J., Zheng, A., Xin, M., & Zhang, S. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111888 · Cited by 73 · see citing works

Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment

Passaro, A., Guerini‐Rocco, E., Pochesci, A., Vacirca, D., Spitaleri, G., Catania, C., Rappa, A., Barberis, M. C. P., & de Marinis, F. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.01.003 · Cited by 73 · see citing works

MET/HGF pathway activation as a paradigm of resistance to targeted therapies

Ko, B., He, T., Gadgeel, S. M., & Halmos, B. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2016.12.09 · Cited by 71 · see citing works

Clinical analysis by next-generation sequencing for NSCLC patients with MET amplification resistant to osimertinib

Wang, Y., Li, L., Han, R., Jiao, L., Zheng, J., & He, Y. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.02.007 · Cited by 66 · see citing works

Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor

Helman, E., Nguyen, M., Karlovich, C., Despain, D., Choquette, A. K., Spira, A. I., Yu, H. A., Camidge, D. R., Harding, T. C., Lanman, R. B., et al. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.07.008 · Cited by 64 · see citing works

First-in-Human Phase I Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Antitumor Activity

Gan, H. K., Millward, M., Ye, H., Qi, C., Sai, Y., Su, W., Wang, J., Zhang, L., Frigault, M. M., Morgan, S. R., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1189 · Cited by 66 · see citing works

Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients

Ou, S. I., Horn, L., Cruz, M. R., Vafai, D., Lovly, C. M., Spradlin, A., Williamson, M. J., Dagogo‐Jack, I., Johnson, A., Miller, V. A., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.07.006 · Cited by 64 · see citing works

Personalized medicine in non-small cell lung cancer: a review from a pharmacogenomics perspective

Jiang, W., Cai, G., Hu, P. C., & Wang, Y. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.04.005 · Cited by 64 · see citing works

Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer

Barnes, T. A., O'Kane, G. M., Vincent, M. D., & Leighl, N. B. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00113 · Cited by 61 · see citing works

Transformation to small-cell carcinoma as an acquired resistance mechanism to AZD9291: A case report

Li, L., Wang, H., Li, C., Wang, Z., Zhang, P., & Xu, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.14506 · Cited by 60 · see citing works

First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor in Non–Small Cell Lung Cancer: Safety, Efficacy, and Potential Mechanism of Resistance

Ma, Y., Zheng, X. X., Zhao, H., Fang, W., Zhang, Y., Ge, J., Wang, L., Wang, W., Jiang, J., Chuai, S., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.03.025 · Cited by 57 · see citing works

Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer

Zhang, K., & Yuan, Q. (2016) · Journal of Cancer Research and Therapeutics · doi:10.4103/0973-1482.200613 · Cited by 57 · see citing works

MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors

Peng, L.-X., Jie, G., Li, A., Liu, S. M., Sun, H., Zheng, M.-M., Zhou, J., Zhang, J., Zhang, X., Zhou, Q. H., et al. (2021) · Experimental Hematology and Oncology · doi:10.1186/s40164-021-00245-y · Cited by 55 · see citing works

The MEK/ERK/miR-21 Signaling Is Critical in Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer Cells

Huang, W.-C., Yadav, V. K., Cheng, W.-H., Wang, C., Hsieh, M., Huang, T., Lin, S., Yeh, C., & Kuo, K.-T. (2021) · Cancers · doi:10.3390/cancers13236005 · Cited by 55 · see citing works

Discovery of 2,4,6-trisubstitued pyrido[3,4-d]pyrimidine derivatives as new EGFR-TKIs

Zhang, H., Wang, J., Shen, Y. H., Wang, H., Duan, W.-M., Zhao, H., Hei, Y., Xin, M., Cao, Y., & Zhang, S. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.02.051 · Cited by 54 · see citing works

A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group

written on behalf of the AME Lung Cancer Collaborative Group, Jiang, T., Su, C., Ren, S., Cappuzzo, F., Rocco, G., Palmer, J. D., van Zandwijk, N., Blackhall, F. H., Le, X., et al. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.07.61 · Cited by 53 · see citing works

Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors

Liao, B.-C., Lin, C., Lee, J., & Yang, J. C. (2016) · Journal of Biomedical Science · doi:10.1186/s12929-016-0305-9 · Cited by 50 · see citing works

Role of Osimertinib in the Treatment of EGFR-Mutation Positive Non-Small-Cell Lung Cancer

Carlisle, J. W., & Ramalingam, S. S. (2019) · Future Oncology · doi:10.2217/fon-2018-0626 · Cited by 50 · see citing works

Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I

Floc’h, N., Lim, S., Bickerton, S., Ahmed, A., Orme, J. P., Urosevic, J., Martin, M. J., Cross, D. A. E., Cho, B. C., & Smith, P. D. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0103 · Cited by 48 · see citing works

Overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanisms

Suda, K., Rivard, C. J., Mitsudomi, T., & Hirsch, F. R. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1355243 · Cited by 49 · see citing works

Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer

Xu, J., Wang, J., & Zhang, S. (2017) · Oncotarget · doi:10.18632/oncotarget.21164 · Cited by 48 · see citing works

The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy

Wang, Y., Tian, P., Xia, L., Li, L., Han, R., Zhu, M., Lizaso, A., Tian, Q., Li, M., Yu, B., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.06.003 · Cited by 48 · see citing works

The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response

Re, M. D., Bordi, P., Rofi, E., Restante, G., Valleggi, S., Minari, R., Crucitta, S., Arrigoni, E., Chella, A., Morganti, R., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0238-z · Cited by 42 · see citing works

Genotype Driven Therapy for Non-Small Cell Lung Cancer: Resistance, Pan Inhibitors and Immunotherapy

Singh, S. S., Dahal, A., Shrestha, L., & Jois, S. D. S. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190222183219 · Cited by 42 · see citing works

Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M

Zhao, S., Li, X., Zhao, C., Jiang, T., Jia, Y., Shi, J., He, Y., Li, J., Zhou, F., Gao, G., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.12.010 · Cited by 40 · see citing works

Sodium cantharidate targets STAT3 and abrogates EGFR inhibitor resistance in osteosarcoma

Ji, X., & He, M. (2019) · Aging · doi:10.18632/aging.102193 · Cited by 37 · see citing works

Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study

Wang, W., Wang, H., Lu, P., Yu, Z., Xu, C., Zhuang, W., & Song, Z. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1803-9 · Cited by 34 · see citing works

Polyphyllin I reverses the resistance of osimertinib in non-small cell lung cancer cell through regulation of PI3K/Akt signaling

Lai, L., Shen, Q., Wang, Y., Chen, L., Lai, J., Wu, Z., & Jiang, H. (2021) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2021.115518 · Cited by 34 · see citing works

MET inhibitor, capmatinib overcomes osimertinib resistance via suppression of MET/Akt/snail signaling in non-small cell lung cancer and decreased generation of cancer-associated fibroblasts

Zhu, K., Lv, Z., Xiong, J., Zheng, H., Zhang, S., Jin, H., Yu, L., Li, Z., Zhang, J., Li, C., et al. (2021) · Aging · doi:10.18632/aging.202547 · Cited by 33 · see citing works

Targeted Therapy Approaches for MET Abnormalities in Non-Small Cell Lung Cancer

Garon, E. B., & Brodrick, P. M. (2021) · Drugs · doi:10.1007/s40265-021-01477-2 · Cited by 31 · see citing works

Differential response to a combination of full-dose osimertinib and crizotinib in a patient with EGFR-mutant non-small cell lung cancer and emergent MET amplification

Zhu, V. W., Schrock, A. B., Ali, S. M., & Ou, S. I. (2019) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s190403 · Cited by 31 · see citing works

Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment

Uchibori, K., Inase, N., Nishio, M., Fujita, N., & Katayama, R. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.04.005 · Cited by 29 · see citing works

Overcoming acquired resistance of gefitinib in lung cancer cells without T790M by AZD9291 or Twist1 knockdown in vitro and in vivo

Liu, Z., & Gao, W. (2019) · Archives of Toxicology · doi:10.1007/s00204-019-02453-2 · Cited by 30 · see citing works

Therapeutic approaches for T790M mutation positive non-small-cell lung cancer

Attili, I., Karachaliou, N., Conte, P., Bonanno, L., & Rosell, R. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1508347 · Cited by 30 · see citing works

Identification of Novel Pathways of Osimertinib Disposition and Potential Implications for the Outcome of Lung Cancer Therapy

MacLeod, A. K., Lin, D., Huang, J. T.-J., McLaughlin, L. A., Henderson, C. J., & Wolf, C. R. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3555 · Cited by 28 · see citing works

A Large Real-World Study on the Effectiveness of the Combined Inhibition of EGFR and MET in EGFR-Mutant Non-Small-Cell Lung Cancer After Development of EGFR-TKI Resistance

Liu, L., Qu, J., Heng, J., Zhou, C., Xiong, Y., Yang, H., Jiang, W., Zeng, L., Zhu, S., Zhang, Y., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.722039 · Cited by 31 · see citing works

Cis-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature

Klempner, S. J., Mehta, P., Schrock, A. B., Ali, S. M., & Ou, S. I. (2017) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s147129 · Cited by 30 · see citing works

The Emerging Role of the c-MET-HGF Axis in Non-small Cell Lung Cancer Tumor Immunology and Immunotherapy

Titmarsh, H. F., O’Connor, R. A., Dhaliwal, K., & Akram, A. R. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00054 · Cited by 29 · see citing works

Acquired Resistance in Oncogene-Addicted Non-Small-Cell Lung Cancer

Sini, C., Tuzi, A., Rossi, G., Russo, A., & Pezzuto, A. (2018) · Future Oncology · doi:10.2217/fon-2018-0097 · Cited by 28 · see citing works

Tet methylcytosine dioxygenase 2 (TET2) deficiency elicits EGFR-TKI (tyrosine kinase inhibitors) resistance in non-small cell lung cancer

Zhang, J., Zhao, K., Zhou, W., Kang, R., Wei, S., Shu, Y., Cheng, Y., Ku, Y., Mao, Y., Luo, H., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01778-4 · Cited by 29 · see citing works

Novel approaches against epidermal growth factor receptor tyrosine kinase inhibitor resistance

Heydt, C., Michels, S. Y. F., Thress, K. S., Bergner, S., Wolf, J., & Buettner, R. (2018) · Oncotarget · doi:10.18632/oncotarget.24624 · Cited by 27 · see citing works

BIM Deletion Polymorphism Confers Resistance to Osimertinib in EGFR T790M Lung Cancer: a Case Report and Literature Review

Li, X., Wang, S., Li, B., Wang, Z., Shang, S., Shao, Y. W., Sun, X., & Wang, L. (2018) · Targeted Oncology · doi:10.1007/s11523-018-0573-2 · Cited by 27 · see citing works

Clinical management of third-generation EGFR inhibitor-resistant patients with advanced non-small cell lung cancer: Current status and future perspectives

Zhang, Y., Zhou, Q. H., & Wu, Y.-L. L. C. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.05.044 · Cited by 27 · see citing works

SHR ‐A1403, a novel c‐mesenchymal‐epithelial transition factor (c‐Met) antibody‐drug conjugate, overcomes AZD 9291 resistance in non‐small cell lung cancer cells overexpressing c‐Met

Tong, M., Gao, M., Xu, Y., Li, F., Li, Y., Bao, X., Fu, H., Quan, H., & Lou, L. (2019) · Cancer Science · doi:10.1111/cas.14180 · Cited by 27 · see citing works

Targeted Therapy for Non-Small Cell Lung Cancer

Noor, Z. S., Cummings, A. L., Johnson, M. M., Spiegel, M. L., & Goldman, J. W. (2020) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0039-1700994 · Cited by 27 · see citing works

Lamellarin 14, a derivative of marine alkaloids, inhibits the T790M/C797S mutant epidermal growth factor receptor

Nishiya, N., Oku, Y., Ishikawa, C., Fukuda, T., Dan, S., Mashima, T., Ushijima, M., Furukawa, Y., Sasaki, Y., Otsu, K., et al. (2021) · Cancer Science · doi:10.1111/cas.14839 · Cited by 24 · see citing works

Modification of osimertinib to discover new potent EGFRC797S-TK inhibitors

Xi, X.-X., Zhao, H., Mao, Y.-Z., Xin, M., & Zhang, S. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115865 · Cited by 25 · see citing works

Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, T790M, and Clinical Trials

O'Kane, G. M., Barnes, T. A., & Leighl, N. B. (2018) · Current Oncology · doi:10.3747/co.25.3796 · Cited by 25 · see citing works

Exploring the resistance mechanisms of second-line osimertinib and their prognostic implications using next-generation sequencing in patients with non-small-cell lung cancer

Lee, K., Kim, D., Yoon, S., Lee, K. H., & Kim, S. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.01.052 · Cited by 25 · see citing works

Resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer

Steen, N. V. D., Giovannetti, E., Carbone, D., Leonetti, A., Rolfo, C. D., & Peters, G. J. (2018) · Cancer Drug Resistance · doi:10.20517/cdr.2018.13 · Cited by 23 · see citing works

Treatment of EGFR T790M-Positive Non-Small Cell Lung Cancer

Choo, J. R.-E., Tan, C., & Soo, R. A. (2018) · Targeted Oncology · doi:10.1007/s11523-018-0554-5 · Cited by 24 · see citing works

Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses

van Veggel, B. A. M. H., de Langen, A. J., Hashemi, S. M. S., Monkhorst, K., Rosenberg, E. H., Heideman, D. A. M., Radonic, T. R., & Smit, E. F. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.07.030 · Cited by 23 · see citing works

Ockham’s razor for the MET-driven invasive growth linking idiopathic pulmonary fibrosis and cancer

Stella, G. M., Gentile, A., Balderacchi, A. M., Meloni, F., Milan, M., & Benvenuti, S. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-1008-4 · Cited by 22 · see citing works

Orthotopic model of lung cancer: isolation of bone micro-metastases after tumor escape from Osimertinib treatment

Jarry, U., Bostoën, M., Pineau, R., Chaillot, L., Mennessier, V., Montagne, P., Motte, E., Gournay, M., Goff, A. L., Guillaudeux, T., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08205-9 · Cited by 22 · see citing works

Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer

Facchinetti, F., Proto, C., Minari, R., Garassino, M. C., & Tiseo, M. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_16 · Cited by 21 · see citing works

Clinical trial designs for evaluating and exploiting cancer evolution

Garces, A. I., Porta, N., Graham, T. A., & Banerji, U. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102583 · Cited by 19 · see citing works

Successful crizotinib monotherapy in EGFR-mutant lung adenocarcinoma with acquired MET amplification after erlotinib therapy

Yoshimura, K., Inui, N., Karayama, M., Inoue, Y., Enomoto, N., Fujisawa, T., Nakamura, Y., Takeuchi, K., Sugimura, H., & Suda, T. (2017) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2017.02.009 · Cited by 20 · see citing works

Efficacy and Safety of Combination Treatment With Apatinib and Osimertinib After Osimertinib Resistance in Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Carcinoma—A Retrospective Analysis of a Multicenter Clinical Study

Yang, X., Xia, Y., Xu, L., Liang, L., Zhuo, M., Wu, M., An, T., Wang, Z., Wang, Y., Li, J., et al. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.639892 · Cited by 20 · see citing works

Prognosis and Concurrent Genomic Alterations in Patients With Advanced NSCLC Harboring MET Amplification or MET Exon 14 Skipping Mutation Treated With MET Inhibitor: A Retrospective Study

Liu, L., Kalyani, F. S., Yang, H., Zhou, C., Xiong, Y., Zhu, S., Yang, N., & Qu, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.649766 · Cited by 19 · see citing works

Targeting MET Amplification: Opportunities and Obstacles in Therapeutic Approaches

Kumaki, Y., Oda, G., & Ikeda, S. (2023) · Cancers · doi:10.3390/cancers15184552 · Cited by 20 · see citing works

Circulating tumor DNA analysis of EGFR-mutant non-small cell lung cancer patients receiving osimertinib following previous tyrosine kinase inhibitor treatment

Beagan, J. J., Bach, S., van Boerdonk, R. A. A., van Dijk, E., Thunnissen, E., van den Broek, D. A., Weiss, M. M., Geert Kazemier, M., Pegtel, D. M., Bahce, I., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.04.039 · Cited by 19 · see citing works

AXL/MET dual inhibitor, CB469, has activity in non-small cell lung cancer with acquired resistance to EGFR TKI with AXL or MET activation

Yang, Y., Jang, Y. J., Lee, S., Kang, B., & Lim, S. M. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.05.031 · Cited by 19 · see citing works

Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR -mutant lung cancer

Eser, P. Ö., Paranal, R. M., Son, J., Ivanova, E. V., Kuang, Y., Haikala, H. M., To, C., Okoro, J. J., Dholakia, K. H., Choi, J., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abb3738 · Cited by 19 · see citing works

EGFR-dependent mechanisms of resistance to osimertinib determined by ctDNA NGS analysis identify patients with better outcome

Vendrell, J. A., Quantin, X., Aussel, A., Solassol, I., Serre, I., & Solassol, J. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-679 · Cited by 16 · see citing works

EGFR exon 19 deletion switch and development of p.L792Q mutation as a new resistance mechanism to osimertinib: a case report and literature review

Pisapia, P., Rocco, D., Pepe, F., Luca, C. D., Battiloro, C., Smeraglio, R., Cieri, M., Bellevicine, C., Troncone, G., & Malapelle, U. (2018) · Translational Cancer Research · doi:10.21037/tcr.2018.09.13 · Cited by 18 · see citing works

Iterative Upgrading of Small Molecular Tyrosine Kinase Inhibitors for EGFR Mutation in NSCLC: Necessity and Perspective

Zhu, J., Yang, Q., & Xu, W. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13091500 · Cited by 17 · see citing works

Three Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Similarities and Differences

Chen, L., Zhou, Y., Gan, C., Wang, X., Liu, Y., Dong, C., He, R., & Yang, J. (2022) · Cancer Investigation · doi:10.1080/07357907.2022.2069254 · Cited by 17 · see citing works

Genomic instability as a major mechanism for acquired resistance to EGFR tyrosine kinase inhibitors in cancer

Liu, B., Duenas, D., Zheng, L., Reckamp, K. L., & Shen, B. (2021) · Protein & Cell · doi:10.1007/s13238-021-00855-6 · Cited by 16 · see citing works

Differential response to a combination of full-dose osimertinib and crizotinib in a patient with EGFR-mutant non-small cell lung cancer and emergent MET amplification

Zhu, V. W., Schrock, A. B., Ali, S. M., & Ou, S. I. (2019) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s190403 · Cited by 31 · see citing works

Heterogeneity‐based, multiple mechanisms in the resistance to osimertinib (AZD9291): A case report

Liu, Y., Hao, X., Hu, X., Li, J., Wang, Y., Wang, H., Xing, P., Li, W., Ying, J., Han, X., et al. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12596 · Cited by 3 · see citing works

Dramatic response to osimertinib combined with crizotinib in EGFR T790 M mutation only in blood and Met amplification only in tumor tissue expressive non-small cell lung cancer

Li, D., Gui, Q., Xu, C., Shen, M., & Chen, K. (2021) · Medicine · doi:10.1097/md.0000000000026375 · Cited by 4 · see citing works

Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report

Blasi, M., Kazdal, D. N., Thomas, M., Christopoulos, P., Kriegsmann, M., Brandt, R., Volckmar, A., Kirchner, M., Heußel, C. P., Stenzinger, A., et al. (2021) · Case Reports in Oncology · doi:10.1159/000513904 · Cited by 11 · see citing works

Response to Dual Crizotinib and Osimertinib Treatment in a Lung Cancer Patient with MET Amplification Detected by Liquid Biopsy Who Acquired Secondary Resistance to EGFR Tyrosine Kinase Inhibition

Deng, L., Kiedrowski, L. A., Ravera, E., Cheng, H., & Halmos, B. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.04.007 · Cited by 56 · see citing works